Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
3,4-Dihydroxy-1-Methylquinolin-2(1h)-One is a synthetic small molecule belonging to the hydroxyquinolone class of organic compounds. It features a quinoline core substituted with two hydroxyl groups at positions 3 and 4 and a methyl group at position 1. The compound has been studied experimentally but is not approved for clinical use in any country. Its primary known molecular target is serine/threonine-protein kinase pim-1 (PIM1), although its pharmacological action on this target remains unclear. There are no reported clinical indications or ongoing clinical trials for this compound[1][2][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 3,4-dihydroxy-1-methylquinolin-2(1h)-one.